Ironwood Pharmaceuticals Stock News

Investing in the biotech sphere isn't for the faint of heart, and you should steer clear of the biotech stocks to avoid. That's because biotech stocks tend to experience wild swings in developments, s

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, trea

Ironwood Pharmaceuticals (NASDAQ: IRWD ) stock is falling on Thursday after the gastrointestinal healthcare company released results from a Phase III clinical trial. This clinical trial covers the

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.

Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.20. This compares to earnings of $0.27 per share a year ago.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Easte

The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42nd Annual J.P. Morgan Healthcare C

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executi

Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved fo

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric

Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro